Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer

M.D. Franken,E.M. van Rooijen,A.M. May,H. Koffijberg,H. van Tinteren,L. Mol,A.J. ten Tije,G.J. Creemers,A.M.T. van der Velden,B.C. Tanis,C.A. Uyl-de Groot,C.J.A. Punt,M. Koopman,M.G.H. van Oijen

European Journal of Cancer（2017）

引用 24|浏览21

暂无评分

摘要

•Compared with observation, CAP-B maintenance was associated with increased costs.•CAP-B maintenance after induction treatment may not be considered cost-effective.

查看译文

关键词

Colorectal,Cancer,Cost-effectiveness,Capecitabine,Bevacizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要